16 results on '"Pečavar, Blaž"'
Search Results
2. Longitudinal trends of recent HIV-1 infections in Slovenia (1986–2012) determined using an incidence algorithm
- Author
-
Lunar, Maja M., Matković, Ivana, Tomažič, Janez, Vovko, Tomaž D., Pečavar, Blaž, and Poljak, Mario
- Published
- 2015
- Full Text
- View/download PDF
3. Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project
- Author
-
Pečavar, Blaž, primary, Kokošar Ulčar, Barbara, additional, Kordiš, Manja, additional, Pleško, Maja, additional, Turel, Gabriele, additional, Vovko, Tomaž, additional, and Tomažič, Janez, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Prevalence of and factors associated with healthcare-associated infections in Slovenian acute care hospitals: Prevalenca in dejavniki, povezani z bolnišničnimi okužbami v slovenskih bolnišnicah za akutno oskrbo: results of the third national survey: rezultati tretje nacionalne presečne raziskave
- Author
-
Klavs, Irena, Korošec, Aleš, Lejko-Zupanc, Tatjana, Pečavar, Blaž, and Serdt, Mojca
- Published
- 2019
5. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
- Author
-
Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi Bee, Jo, Lim, Wei Shen, Al Mamun, Abdullah, Anovadiya, Ashish P., Araújo, Wildo N., Azziz Baumgartner, Eduardo, Báez, Clarisa, Bantar, Carlos, Barhoush, Mazen M., Bassetti, Matteo, Beovic, Bojana, Bingisser, Roland, Bonmarin, Isabelle, Borja Aburto, Victor H., Cao, Bin, Carratala, Jordi, Cuezzo, María R., Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A. D., Dubnov Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Fraser, James, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoeger, Peter H., Hoffmann, Matthias, Xiaoyun, Hu, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Khandaker, Gulam, Knight, Marian, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Lahlou Amine, Idriss, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee Sin, Linko, Rita, Liu, Pei, Madanat, Faris, Manabe, Toshie, Mayo Montero, Elga, Mcgeer, Allison, Memish, Ziad A., Metan, Gokhan, Mikić, Dragan, Mohn, Kristin G. I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Ozbay, Bulent, Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Poeppl, Wolfgang, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Siqueira, Marilda M., Skrȩt Magierło, Joanna, Talarek, Ewa, Tang, Julian W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelies, Vaudry, Wendy, Velyvyte, Daiva, Vidmar, Tjasa, Zarogoulidis, Paul, Nguyen Van Tam, Jonathan S, de Lourdes Aguiar Oliveira, Maria, Al Khuwaitir, Tarig S. A., Al Masri, Malakita, Amin, Robed, Ballester Orcal, Elena, Bao, Jing, Basher, Ariful, Bautista, Edgar, Bertisch, Barbara, Bettinger, Julie, Booy, Robert, Bouza, Emilio, Bozkurt, Ilkay, Burgmann, Heinz, Čeljuska Tošev, Elvira, Chan, Kenny K. C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Sarrouf, Elena B., Cui, Wei, Dashti Khavidaki, Simin, Bin, Du, El Rhaffouli, Hicham, Escobar, Hernan, Florek Michalska, Agnieszka, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Honarvar, Behnam, Jianming, Hu, Kemen, Christoph, Koay, Evelyn S. C., Kojic, Miroslav, Kudo, Koichiro, Kyaw, Win M., Leibovici, Leonard, Xiao li, Li, Hongru, Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratios, Marcone, Debora N., Marczynska, Magdalena, Mastalir, Fabiane P., Mickiene, Aukse, Moghadami, Mohsen, Moriconi, Lilian, Oliva, Maria E., Pečavar, Blaž, Poliquin, Philippe G., Rahman, Mahmudur, Rascon Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Seale, Anna C., Sertogullarindan, Bunyamin, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Stephan, Frank, Tabarsi, Payam, Tripathi, C. B., Viasus, Diego, Qin, Yu, Zhang, Wei, Zuo, Wei, Universitat de Barcelona, Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', Institut de Veille Sanitaire (INVS), Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Diseases, Department of physics, engineering physics and astronomy, Queen's University [Kingston, Canada], Peking University People's Hospital, Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Centre National de la Recherche Scientifique (CNRS)-IRD-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de La Réunion (UR), National Perinatal Epidemiology Unit, University of Oxford [Oxford], Instituto Nacional de Enfermedades Respiratorias Dr. Emilio Coni [Santa Fe, Argentina] (INER), State Key Laboratory of Advanced Electromagnetic Engineering and Technology, Huazhong University of Science and Technology [Wuhan] (HUST), People's Hospital of Peking University (PKUPH), Université de La Réunion (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IRD-Centre National de la Recherche Scientifique (CNRS), University of Oxford, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi Bee, Jo, Lim, Wei Shen, Al Mamun, Abdullah, Anovadiya, Ashish P., Araújo, Wildo N., Azziz Baumgartner, Eduardo, Báez, Clarisa, Bantar, Carlo, Barhoush, Mazen M., Bassetti, Matteo, Beovic, Bojana, Bingisser, Roland, Bonmarin, Isabelle, Borja Aburto, Victor H., Cao, Bin, Carratala, Jordi, Cuezzo, María R., Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A. D., Dubnov Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Fraser, Jame, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoeger, Peter H., Hoffmann, Matthia, Xiaoyun, Hu, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Khandaker, Gulam, Knight, Marian, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Lahlou Amine, Idri, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Manabe, Toshie, Mayo Montero, Elga, Mcgeer, Allison, Memish, Ziad A., Metan, Gokhan, Mikić, Dragan, Mohn, Kristin G. I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Ozbay, Bulent, Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Poeppl, Wolfgang, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Siqueira, Marilda M., Skrȩt Magierło, Joanna, Talarek, Ewa, Tang, Julian W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Velyvyte, Daiva, Vidmar, Tjasa, Zarogoulidis, Paul, Nguyen Van Tam, Jonathan S, de Lourdes Aguiar Oliveira, Maria, Al Khuwaitir, Tarig S. A., Al Masri, Malakita, Amin, Robed, Ballester Orcal, Elena, Bao, Jing, Basher, Ariful, Bautista, Edgar, Bertisch, Barbara, Bettinger, Julie, Booy, Robert, Bouza, Emilio, Bozkurt, Ilkay, Burgmann, Heinz, Čeljuska Tošev, Elvira, Chan, Kenny K. C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Sarrouf, Elena B., Cui, Wei, Dashti Khavidaki, Simin, Bin, Du, El Rhaffouli, Hicham, Escobar, Hernan, Florek Michalska, Agnieszka, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Honarvar, Behnam, Jianming, Hu, Kemen, Christoph, Koay, Evelyn S. C., Kojic, Miroslav, Kudo, Koichiro, Kyaw, Win M., Leibovici, Leonard, Xiao li, Li, Hongru, Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Marcone, Debora N., Marczynska, Magdalena, Mastalir, Fabiane P., Mickiene, Aukse, Moghadami, Mohsen, Moriconi, Lilian, Oliva, Maria E., Pečavar, Blaž, Poliquin, Philippe G., Rahman, Mahmudur, Rascon Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Seale, Anna C., Sertogullarindan, Bunyamin, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Stephan, Frank, Tabarsi, Payam, Tripathi, C. B., Viasus, Diego, Qin, Yu, Zhang, Wei, Zuo, Wei, Pediatric surgery, and ICaR - Circulation and metabolism
- Subjects
Hospitalisation ,Individual participant data meta-analyses ,Influenza-related pneumonia ,Neuraminidase inhibitors ,Adolescent ,Adrenal Cortex Hormones ,Adult ,Anti-Bacterial Agents ,Antiviral Agents ,Child ,Child, Preschool ,Enzyme Inhibitors ,Female ,Humans ,Influenza, Human ,Male ,Middle Aged ,Neuraminidase ,Odds Ratio ,Pneumonia, Viral ,Treatment Outcome ,Young Adult ,Influenza A Virus, H1N1 Subtype ,0301 basic medicine ,Epidemiology ,[SDV]Life Sciences [q-bio] ,viruses ,Meta-análises de dados de participantes individuais ,Antibiotics ,Pneumònia ,Adrenal Cortex Hormone ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit ,influenza-related pneumonia ,neuraminidase inhibitors ,0302 clinical medicine ,individual participant data meta‐analyses ,Influenza A Virus ,Enzyme Inhibitor ,030212 general & internal medicine ,Viral ,Incidence (epidemiology) ,Inibidores da neuraminidase ,virus diseases ,3. Good health ,Hospitalization ,Infectious Diseases ,Meta-analysis ,Original Article ,Individual participant data meta-analyse ,Public Health ,Human ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Antagonists & inhibitors ,medicine.drug_class ,influenza-related pneumonia ,030106 microbiology ,influenza‐related pneumonia ,Neuraminidase inhibitor ,Ingressos i altes en els hospitals ,Public Health, Environmental and Occupational Health ,03 medical and health sciences ,Open Access ,Pneumonia relacionada à gripe ,Pharmacotherapy ,Internal medicine ,Anti-Bacterial Agent ,medicine ,H1N1 Subtype ,Preschool ,Antiviral Agent ,Hospitalização ,Hospital admission and discharge ,business.industry ,Environmental and Occupational Health ,individual participant data meta-analyses ,Original Articles ,Odds ratio ,Pneumonia ,medicine.disease ,Influenza ,respiratory tract diseases ,El Niño ,Immunology ,business - Abstract
Stella G. Muthuri,1 Sudhir Venkatesan,1 Puja R. Myles,1 Jo Leonardi-Bee,1 Wei Shen Lim,2 Abdullah Al Mamun,3 Ashish P. Anovadiya,4 Wildo N. Ara ujo,5 Eduardo Azziz-Baumgartner,6 Clarisa B aez,7 Carlos Bantar,8 Mazen M. Barhoush,9 Matteo Bassetti,10 Bojana Beovic,11 Roland Bingisser,12 Isabelle Bonmarin,13 Victor H. Borja-Aburto,14 Bin Cao,15 Jordi Carratala,16 Mar ıa R. Cuezzo,17 Justin T. Denholm,18 Samuel R. Dominguez,19 Pericles A. D. Duarte,20 Gal Dubnov-Raz,21 Marcela Echavarria,22 Sergio Fanella,23 James Fraser,24 Zhancheng Gao,25 Patrick G erardin,26,27,28,29 Maddalena Giannella,30 Sophie Gubbels,31 Jethro Herberg,32 Anjarath L. Higuera Iglesias,33 Peter H. Hoeger,34 Matthias Hoffmann,35 Xiaoyun Hu,36 Quazi T. Islam,37 Mirela F. Jim enez,38 Amr Kandeel,39 Gerben Keijzers,40 Hossein Khalili,41 Gulam Khandaker,42 Marian Knight,43 Gabriela Kusznierz,44 Ilija Kuzman,45 Arthur M. C. Kwan,46 Idriss Lahlou Amine,47 Eduard Langenegger,48 Kamran B. Lankarani,49 Yee-Sin Leo,50 Rita Linko,51 Pei Liu,52 Faris Madanat,53 Toshie Manabe,54 Elga Mayo-Montero,55 Allison McGeer,56 Ziad A. Memish,57,58 Gokhan Metan,59 Dragan Miki c,60 Kristin G. I. Mohn,61,62 Ahmadreza Moradi,63,64 Pagbajabyn Nymadawa,65 Bulent Ozbay,66 Mehpare Ozkan,67 Dhruv Parekh,68 Mical Paul,69 Wolfgang Poeppl,70 Fernando P. Polack,71,72 Barbara A. Rath,73 Alejandro H. Rodr ıguez,74 Marilda M. Siqueira,75 Joanna Skre zt-Magierło,76 Ewa Talarek,77 Julian W. Tang,78,79,80 Antoni Torres,81 Selda H. T€ or€un,82 Dat Tran,83 Timothy M. Uyeki,84 Annelies van Zwol,85 Wendy Vaudry,86 Daiva Velyvyte,87 Tjasa Vidmar,88 Paul Zarogoulidis,89 PRIDE Consortium Investigators* Jonathan S. Nguyen-Van-Tam1 1Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK. 2Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK. 3International Centre for Diarrhoeal Diseases, Research Bangladesh (ICDDRB), Dhaka, Bangladesh. 4Department of Pharmacology, Government Medical College and Sir Takhtsinhji General Hospital, Bhavnagar, Gujarat, India. 5University of Bras ılia, Bras ılia, DF, Brazil. 6Centers for Disease Control and Prevention, Atlanta, GA, USA. 7Ministerio de Salud de la Provincia de Buenos Aires, Buenos Aires, Argentina. 8Department of Infection Control, Hospital San Mart ın de Paran a, Entre R ıos, Argentina. 9Department of Medicine, King Saud Medical City, Riyadh, Saudi Arabia. 10Santa Maria Misericordia Hospital, Udine, Italy. 11Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia. 12Department of Emergency Medicine, University Hospital Basel, Basel, Switzerland. 13Institut de Veille Sanitaire, Saint-Maurice, France. 14Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. 15Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. 16Department of Infectious Diseases, Hospital Universitari de Bellvitge, Bellvitge Institute for Biomedical Research, L’Hospitalet de Llobregat, Red Espa~nola de Investigaci on en Patolog ıa Infecciosa, University of Barcelona, Barcelona, Spain. 17Ministerio de Salud de Tucum an, Tucum an, Argentina. 18Victorian Infectious Diseases Service and Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Parkville, Vic., Australia. 19Department of Pediatric Infectious Diseases, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA. 20Universidade Estadual do Oeste do Parana ´, UNIOESTE, Cascavel, PR, Brazil. 21The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hashomer, Israel. 22Clinical Virology Laboratory, CEMIC University Hospital, Buenos Aires, Argentina. 23Section of Pediatric Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada. 24Paediatric Intensive Care Unit, Bristol Children’s Hospital, Bristol, UK. 25Department of Respiratory & Critical Care Medicine, Peking University People’s Hospital, Beijing, China. 26NICU/PICU, PFME, CHU Saint Pierre, Saint Pierre, La R eunion, France. 27CIC 1410 (CHU/Inserm/University of La Re ´union/URML-OI), CHU Saint Pierre, Saint Pierre, La Réunion, France. 28UMR PIMIT (CHU/Inserm/University of La Re ´union/IRD/CNRS), CYROI, Saint Denis – Reunion Island, Saint Denis, France. 29NICU/PICU CHU of La Re ´union, Groupe Hospitalier Sud Re ´union, Saint Pierre, La Re ´union, France. 30Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Maran ˜o ´n, Madrid, Spain. 31Department of Infectious Disease Epidemiology, Sector for National Health Documentation and Research, Statens Serum Institut, Copenhagen, Denmark. 32Section of Paediatrics, Division of Infectious Disease, Imperial College, London, UK. 33Epidemiology Research Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosı ´o Villegas, Mexico City, Mexico. 34Cath. Children’s Hospital Wilhelmstift, Hamburg, Germany. 35Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 36Peking Union Medical College Hospital, Beijing, China. 37Dhaka Medical College Hospital, Dhaka, Bangladesh. 38Departamento de Ginecologia e Obstetrı ´cia – UFCSPA, Preceptora da Reside ˆncia Me ´dica do Hospital Fe ˆmina, Porto Alegre, Brazil. 39Ministry of Health in Egypt, Cairo, Egypt. 40Gold Coast Hospital, Gold Coast, Qld, Australia. 41Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 42National Centre for Immunisation Research and Surveillance (NCIRS), The Children’s Hospital at Westmead, University of Sydney, Sydney, NSW, Australia. 43National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. 44National Institute of Respiratory Diseases ‘Emilio Coni’ ANLIS “C. Malbran”, Santa Fe, Argentina. 45School of Medicine, University Hospital for Infectious Diseases, University of Zagreb, Zagreb, Croatia. 46Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong. 47Faculty of Medicine and Pharmacy, Mohammed V Military Teaching Hospital, Biosafety Level 3 and Research Laboratory, University Mohammed V-Souissi, Rabat, Morocco. 48Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg, Stellenbosch, South Africa. 49Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 50Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. 51Helsinki University Hospital, Helsinki, Finland. 52Department of Infectious Diseases, The First Affiliated Hospital, China Medical University, Shenyang, China. 53Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan. 54Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan. 55Instituto de Medicina Preventiva de la Defensa, Capitan Medico Ramon y Cajal (IMPDEF), Ministerio de Defensa, Madrid, Spain. 56Toronto Invasive Bacterial Diseases Network, University of Toronto, Toronto, ON, Canada. 57Ministry of Health, Riyadh, Saudi Arabia. 58College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. 59Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey. 60Military Medical Academy, Clinic for Infectious and Tropical Diseases, Belgrade, Serbia. 61Section for Infectious Diseases, Medical Department, and Department of Research and Development, Haukeland University Hospital, Bergen, Norway. 62Department of Clinical Science, The Influenza Centre, University of Bergen, Bergen, Norway. 63The Division of Ocular Immunology, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 64National Research Institute for Tuberculosis and Lung Disease, Massih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 65National Influenza Center, National Center of Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia. 66Department of Pulmonary and Critical Care, Yuzuncu Yil University Medical Faculty, Van, Turkey. 67Clinic of Pediatric Neurology, Dr. Sami Ulus Research and Training Hospital of Women’s and Children’s Health and Diseases, Ankara, Turkey. 68Critical Care and Pain Perioperative, Critical Care and Trauma Trials Group, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK. 69Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel. 70Medical University of Vienna, Vienna, Austria. 71Department of Pediatrics, Vanderbilt Vaccine Center, Vanderbilt University, Nashville, TN, USA. 72Fundacion INFANT, Buenos Aires, Argentina. 73Division of Pneumonology-Immunology, Department of Pediatrics, Charite ´ University Medical Center, Berlin, Germany. 74Critical Care Department, Hospital Joan XXIII, IISPV, URV, CIBERES, Tarragona, Spain. 75Laboratory of Respiratory Viruses, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro, Brazil. 76Uniwersytet Rzeszowski, Rzeszo ´w, Poland. 77Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. 78Division of Microbiology/Molecular Diagnostic Centre, Department of Laboratory Medicine, National University Hospital, Singapore, Singapore. 79Alberta Provincial Laboratory for Public Health, University of Alberta Hospital, Edmonton, Canada. 80Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada. 81Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain. 82Department of Pediatric Infectious Diseases, Istanbul Medical Faculty, Istanbul, Turkey. 83Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Canada. 84Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 85Department of Pediatric Intensive Care, VU University Medical Center, Amsterdam, The Netherlands. 86Division of Infectious Diseases, Department of Pediatrics, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada. 87Lithuanian University of Health Sciences, Kaunas, Lithuania. 88General Hospital, Slovenj Gradec, Slovenia. 89Unit of Infectious Diseases, University General Hospital of Alexandroupolis, Democritus University Thrace, Dragana, Greece. Correspondence: Jonathan S. Nguyen-Van-Tam, University of Nottingham, City Hospital, DM, Room A28b, Clinical Sciences Building, Nottingham NG5 1PB, UK. E-mail: jvt@nottingham.ac.uk *List of PRIDE Consortium Investigators are in Appendix 1. For affiliations, please see Table S1. Múltipla - ver em notas Background The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1) pdm09 virus infection. Methods A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A (H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) ‘pandemic influenza’. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. Results Of 20 634 included participants, 5978 (29 0%) had IRP; conversely, 3349 (16 2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0 83 (95% CI 0 64–1 06; P = 0 136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0 72 (0 44–1 17; P = 0 180)] or likelihood of requiring ventilatory support [adj. OR = 1 17 (0 71– 1 92; P = 0 537)], but early treatment versus later significantly reduced mortality [adj. OR = 0 70 (0 55–0 88; P = 0 003)] and likelihood of requiring ventilatory support [adj. OR = 0 68 (0 54– 0 85; P = 0 001)]. Conclusions Early NAI treatment of patients hospitalised with A (H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.
- Published
- 2016
6. HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011–2016 update
- Author
-
Lunar, Maja M., primary, Židovec Lepej, Snježana, additional, Tomažič, Janez, additional, Vovko, Tomaž D., additional, Pečavar, Blaž, additional, Turel, Gabriele, additional, Maver, Manja, additional, and Poljak, Mario, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Prevalence of HIV Type 1 Transmitted Drug Resistance in Slovenia: 2005-2010
- Author
-
Lunar, Maja M., Židovec Lepej, Snježana, Abecasis, Ana B., Tomažič, Janez, Vidmar, Ludvik, Karner, Primož, Vovko, Tomaž D., Pečavar, Blaž, Maver, Polona J., Seme, Katja, and Poljak, Mario
- Subjects
prevalence ,HIV type 1 ,transsmmitted drug resistance ,Slovenia - Abstract
Slovenia is a small European country with a total of 547 HIV-infected individuals cumulatively reported by the end of 2011. However, the estimated incidence rate of HIV infections increased from 7.0 per million in 2003 to 26.8 per million in 2011. In this study, we assessed the prevalence of transmitted drug resistance (TDR) in the past 6 years (2005–2010) and analyzed the time trend of the proportion of men having sex with men (MSM) and HIV-1 subtype B among newly diagnosed individuals in a 15-year period (1996–2010) in Slovenia. Among 150 patients included in the study, representing 63% of HIV-1 newly diagnosed patients in 2005–2010, TDR was found in seven patients (4.7%). The prevalence of TDR to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors was 2% (3/150), 2% (3/150), and 0.7% (1/150), respectively. The majority of patients were infected with subtype B (134/150, 89%), while subtype A was detected in 6.0% (9/150), subtype D in 1.3% (2/150), and subtype G and CRF02_AG in 0.7% (one patient each). Three of 150 sequences could not be typed. Infection with subtype B was found to be significantly associated with male gender, Slovenia being reported as the country of the patient's nationality and origin of the virus, CDC class A, mode of transmission with homosexual/bisexual contact, sex with an anonymous person, and a higher CD4+ count. Among patients carrying the subtype B virus, an MSM transmission route was reported in 87% of patients. Although the prevalence of TDR in Slovenia is still below the European average, active surveillance should be continued, especially among MSM, the most vulnerable population for HIV-1 infection in this part of Europe.
- Published
- 2013
8. Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe
- Author
-
Lunar, Maja M, primary, Vandamme, Anne-Mieke, additional, Tomažič, Janez, additional, Karner, Primož, additional, Vovko, Tomaž D, additional, Pečavar, Blaž, additional, Volčanšek, Gabriele, additional, Poljak, Mario, additional, and Abecasis, Ana B, additional
- Published
- 2015
- Full Text
- View/download PDF
9. Tick borne encephalitis without cerebrospinal fluid pleocytosis
- Author
-
Stupica, Daša, primary, Strle, Franc, additional, Avšič-Županc, Tatjana, additional, Logar, Mateja, additional, Pečavar, Blaž, additional, and Bajrović, Fajko F, additional
- Published
- 2014
- Full Text
- View/download PDF
10. Prevalence, genotype distribution, and risk factors for hepatitis C infection among HIV-infected individuals in Slovenia: a 1986–2013 update
- Author
-
Škamperle, Mateja, primary, Seme, Katja, additional, Lunar, Maja M., additional, Maver, Polona J., additional, Tomažič, Janez, additional, Vovko, Tomaž D., additional, Pečavar, Blaž, additional, Matičič, Mojca, additional, and Poljak, Mario, additional
- Published
- 2014
- Full Text
- View/download PDF
11. Low prevalence of hepatitis C infection among HIV-infected individuals in Slovenia: a nationwide study, 1985–2013
- Author
-
Seme, Katja, primary, Škamperle, Mateja, additional, Lunar, Maja M, additional, Vodičar, Polona Maver, additional, Tomažič, Janez, additional, Vidmar, Ludvik, additional, Karner, Primož, additional, Vovko, Tomaž, additional, Pečavar, Blaž, additional, Matičič, Mojca, additional, and Poljak, Mario, additional
- Published
- 2014
- Full Text
- View/download PDF
12. The characteristics of the HIV subtype B epidemic in Slovenia
- Author
-
Lunar, Maja M, primary, Abecasis, Ana B, additional, Vandamme, Anne-Mieke, additional, Tomažič, Janez, additional, Vidmar, Ludvik, additional, Karner, Primož, additional, Vovko, Tomaž D, additional, Pečavar, Blaž, additional, and Poljak, Mario, additional
- Published
- 2014
- Full Text
- View/download PDF
13. Short Communication: Prevalence of HIV Type 1 Transmitted Drug Resistance in Slovenia: 2005–2010
- Author
-
Lunar, Maja M., primary, Židovec Lepej, Snježana, additional, Abecasis, Ana B., additional, Tomažič, Janez, additional, Vidmar, Ludvik, additional, Karner, Primož, additional, Vovko, Tomaž D., additional, Pečavar, Blaž, additional, Maver, Polona J., additional, Seme, Katja, additional, and Poljak, Mario, additional
- Published
- 2013
- Full Text
- View/download PDF
14. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
- Author
-
Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Al Khuwaitir, TSA, Al Mamun, A, Anovadiya, AP, Azziz-Baumgartner, E, Báez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoger, PH, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, AMC, Amine, IL, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Polack, FP, Rath, BA, Rodríguez, AH, Sarrouf, EB, Seale, AC, Sertogullarindan, B, Siqueira, MM, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, JW, To, KKW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, RTC, Zarogoulidis, P, Nguyen-van-Tam, JS, Aguiar-Oliveira, ML, Al Masri, M, Amin, R, Araújo, WN, Ballester-Orcal, E, Bantar, C, Bao, J, Barhoush, MM, Basher, A, Bautista, E, Bettinger, J, Bingisser, R, Bouza, E, Bozkurt, I, Celjuska-Tošev, E, Chan, KKC, Chen, Y, Chinbayar, T, Cilloniz, C, Cox, RJ, Cuezzo, MR, Cui, W, Dashti-Khavidaki, S, du, B, El Rhaffouli, H, Escobar, H, Florek-Michalska, A, Fraser, J, Gerrard, J, Gormley, S, Götberg, S, Hoffmann, M, Honarvar, B, Hu, J, Kemen, C, Khandaker, G, Koay, KSC, Kojic, M, Kyaw, WM, Leibovici, L, Li, H, Li, X-L, Libster, R, Loh, TP, Macbeth, D, Maltezos, E, Manabe, T, Marcone, DN, Marczynska, M, Mastalir, FP, Moghadami, M, Moriconi, L, Ozbay, B, Pečavar, B, Poeppl, W, Poliquin, PG, Rahman, M, Rascon-Pacheco, A, Refaey, S, Schweiger, B, Smith, FG, Somer, A, Souza, TML, Tabarsi, P, Tripathi, CB, Velyvyte, D, Viasus, D, Yu, Q, Yuen, K-Y, Zhang, W, Zuo, W, Pediatric surgery, CCA - Innovative therapy, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi-Bee, Jo, Al Khuwaitir, Tarig S. A., Al Mamun, Adbullah, Anovadiya, Ashish P., Azziz-Baumgartner, Eduardo, Báez, Clarisa, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H., Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A.D., Dubnov-Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoger, Peter H., Hu, Xiaoyun, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Knight, Marian, Kudo, Koichiro, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Amine, Idriss Lahlou, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee-Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Mayo-Montero, Elga, Mcgeer, Allison, Memish, Ziad, Metan, Gokhan, Mickiene, Aukse, Mikic, Dragan, Mohn, Kristin G.I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Oliva, Maria E., Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Sarrouf, Elena B., Seale, Anna C., Sertogullarindan, Bunyamin, Siqueira, Marilda M., Skret-Magierlo, Joanna, Stephan, Frank, Talarek, Ewa, Tang, Julian W., To, Kelvin K.W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Vidmar, Tjasa, Yokota, Renata T.C., Zarogoulidis, Paul, Nguyen-van-Tam, Jonathan S, Aguiar-Oliveira, Maria de Lourde, Al Masri, Malakita, Amin, Robed, Araújo, Wildo N., Ballester-Orcal, Elena, Bantar, Carlo, Bao, Jing, Barhoush, Mazen M., Basher, Ariful, Bautista, Edgar, Bettinger, Julie, Bingisser, Roland, Bouza, Emilio, Bozkurt, Ilkay, Celjuska-Tošev, Elvira, Chan, Kenny K.C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Cuezzo, María R., Cui, Wei, Dashti-Khavidaki, Simin, Du, Bin, El Rhaffouli, Hicham, Escobar, Hernan, Florek-Michalska, Agnieszka, Fraser, Jame, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Hoffmann, Matthia, Honarvar, Behnam, Hu, Jianmin, Kemen, Christoph, Khandaker, Gulam, Koay, Evelyn S. C., Kojic, Miroslav, Kyaw, Win M., Leibovici, Leonard, Li, Hongru, Li, Xiao-Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Manabe, Toshie, Marcone, Débora N., Marczynska, Magdalena, Mastalir, Fabiane P., Moghadami, Mohsen, Moriconi, Lilian, Ozbay, Bulent, Pečavar, Blaž, Poeppl, Wolfgang, Poliquin, Philippe G., Rahman, Mahmudur, Rascon-Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Tabarsi, Payam, Tripathi, Chandrabhanu B., Velyvyte, Daiva, Viasus, Diego, Yu, Qin, Yuen, Kwok-Yung, Zhang, Wei, and Zuo, Wei
- Subjects
Male ,ANTIVIRAL TREATMENT ,IMPACT ,Respiratory System ,CHILDREN ,Neuraminidase inhibitors ,Pandemic influenza ,Mortality ,Meta-analysis ,medicine.disease_cause ,THERAPY ,chemistry.chemical_compound ,Influenza A Virus, H1N1 Subtype ,0302 clinical medicine ,Pandemic ,Influenza A Virus ,Influenza A virus ,Zanamivir ,030212 general & internal medicine ,Enzyme Inhibitors ,Child ,OUTCOMES ,0303 health sciences ,biology ,Neuraminidase inhibitor ,Medicine (all) ,virus diseases ,Middle Aged ,3. Good health ,Hospitalization ,Treatment Outcome ,Female ,Life Sciences & Biomedicine ,Adolescent ,Adult ,Antiviral Agents ,Humans ,Influenza, Human ,Neuraminidase ,Oseltamivir ,Proportional Hazards Models ,Young Adult ,Pandemics ,Pulmonary and Respiratory Medicine ,Human ,medicine.drug ,medicine.medical_specialty ,medicine.drug_class ,PANDEMIC INFLUENZA ,Article ,PRIDE Consortium Investigators ,03 medical and health sciences ,Critical Care Medicine ,General & Internal Medicine ,Internal medicine ,medicine ,H1N1 Subtype ,Intensive care medicine ,Science & Technology ,030306 microbiology ,business.industry ,STEM-CELL TRANSPLANTATION ,ADULTS ,Odds ratio ,Influenza ,chemistry ,RISK-FACTORS ,biology.protein ,business - Abstract
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70-0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41-0·56; p
- Published
- 2014
15. HIV-1 subtype diversity and phylogenetic insight into non-B subtype transmission in Slovenia, 1989-2013.
- Author
-
Mlakar J, Lunar MM, Abecasis AB, Vandamme AM, Tomažič J, Vovko TD, Pečavar B, Turel G, and Poljak M
- Subjects
- Male, Humans, Slovenia epidemiology, Phylogeny, Homosexuality, Male, HIV-1 genetics, Sexual and Gender Minorities, HIV Infections epidemiology
- Abstract
Introduction: Disease progression, drug resistance mutations, and treatment strategies may vary by HIV-1 subtype. This study determined HIV-1 subtypes circulating in Slovenia, a Central European country with an HIV-1 epidemic driven by men who have sex with men, focusing on molecular epidemiology of non-B subtypes., Methods: A total of 367 HIV-1 sequences were included. Subtype was assigned by employing eight different HIV subtyping tools coupled with maximum likelihood phylogenetic analyses., Results: The subtyping tools COMET, jpHMM, and REGA 3.0 exhibited the best performance on the dataset studied. Phylogenetic analyses showed a 14.7% prevalence of non-B subtypes, with subtype A detected most frequently (4.9%), followed by CRF02_AG (2.4%), subtype C (1.1%), subtypes D, G, and CRF01_AE (0.8% each), and subtypes F and CRF22_01A1 (0.3% each). A subtype could not be assigned to 12 sequences (3.3%), indicating potential unique recombinant forms. Non-B subtypes were significantly associated with a heterosexual route of transmission and infection acquired in Eastern Europe, Africa, or Asia., Conclusion: In a country where subtype B is predominant, non-B subtypes were observed in one out of seven patients, a non-negligible proportion, which underlines the importance of systematic surveillance of HIV subtype diversity and the corresponding molecular epidemiology.
- Published
- 2023
16. Acute kidney injury in critically-ill adult patients with seasonal influenza infection.
- Author
-
Dovč A, Premru V, Pečavar B, and Ponikvar R
- Subjects
- Acute Kidney Injury epidemiology, Acute Kidney Injury therapy, Adult, Aged, Critical Illness, Female, Humans, Incidence, Male, Middle Aged, Renal Replacement Therapy, Retrospective Studies, Seasons, Acute Kidney Injury etiology, Influenza, Human complications
- Abstract
Background: Acute kidney injury (AKI) occurs in 22.4 - 100% of critically-ill hospitalized patients with influenza infection. In up to 2/3, it is severe enough to necessitate renal replacement therapy. We aimed to document the incidence of AKI among patients with influenza-related critical illness and its relation to clinical outcomes., Methods: We conducted a retrospective observational study of all adult patients with acute respiratory illness and laboratory-confirmed influenza infection admitted to non-surgical intensive care units at the University Medical Centre Ljubljana between January 1, 2016, and March 31, 2016., Result: Our sample consisted of 28 adult patients with mean age in years of 57.5 ± 20.2. Incidence of AKI was 71.4%. Mortality was 28.6% (35% in patients with AKI and 41.6% in patients who required renal replacement therapy)., Conclusions: Influenza-related critical illness is rare but can cause AKI in a large proportion of affected patients. In this setting, requirement for renal replacement therapy could be associated with increased mortality risk. .
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.